Welcome to our dedicated page for Phio Pharmaceuticals news (Ticker: PHIO), a resource for investors and traders seeking the latest updates and insights on Phio Pharmaceuticals stock.
Phio Pharmaceuticals Corp (NASDAQ: PHIO) is a clinical-stage biotechnology pioneer developing next-generation immuno-oncology therapies using its proprietary INTASYL® RNAi platform. This page provides centralized access to official press releases, clinical trial updates, and strategic partnership announcements related to PHIO's innovative approach to enhancing immune cell function against cancer.
Investors and researchers will find timely updates on PHIO's progress in silencing immune checkpoint targets like PD-1 and TIGIT through its self-delivering siRNA technology. The resource covers key developments including clinical trial milestones, collaborative research findings, and regulatory advancements for therapies like lead candidate PH-762.
Content spans multiple categories essential for tracking biopharmaceutical innovation: clinical trial results, research collaborations with institutions like Gustave Roussy, intellectual property updates, and technology licensing agreements. Each update is sourced directly from company disclosures to ensure reliability.
Bookmark this page for streamlined monitoring of PHIO's advancements in RNAi-based cancer therapeutics. Check regularly for new developments in their mission to overcome tumor-induced immunosuppression through precision gene silencing.
Phio Pharmaceuticals Corp. (Nasdaq: PHIO) will participate in the H.C. Wainwright 23rd Annual Global Investment Conference, taking place virtually from September 13 to 15, 2021. Dr. Gerrit Dispersyn, President & CEO, will present on September 13 at 7:00 AM ET. A webcast of the presentation will be available, with replays accessible on the company's website for 90 days. Phio focuses on developing immuno-oncology therapeutics using its proprietary INTASYL platform, aimed at enhancing immune response against tumors.
Phio Pharmaceuticals Corp. (Nasdaq: PHIO) has announced that it will present new clinical study data at the ESMO Virtual Congress 2021 from September 16-21, 2021. The presentation will focus on dual targeting PD-1 and BRD4 using the company's proprietary INTASYL self-delivering RNAi platform, aiming to elicit persistent anti-tumor immunity following tumor resolution. The abstract number for this presentation is #4154. Archived details will be available on the Company's website in the Investors section.
Phio Pharmaceuticals Corp. (Nasdaq: PHIO) reported its financial results for Q2 2021, showing a net loss of $2.7 million. The company has $29.4 million in cash, sufficient to fund operations through Q2 2023. Phio is advancing its INTASYL™ platform, with promising preclinical data for its lead asset, PH-762, aimed at PD-1 in cancer treatment. Clinical trials are set to begin in 2022, with expected milestones including first-in-human studies for melanoma. R&D expenses increased to $1.7 million, reflecting expanded clinical preparation.
Phio Pharmaceuticals Corp. (Nasdaq: PHIO) will participate in a Fireside Chat with H.C. Wainwright on July 12, 2021, at 11 a.m. Eastern Time. The event aims to discuss the company’s advancements in immuno-oncology therapeutics utilizing its INTASYL™ RNAi platform, designed to boost immune responses against tumors. Interested listeners should register in advance to access the live audio. The webcast will be archived for 90 days on the company’s website. For more information on Phio's innovative therapies, visit their site.
Phio Pharmaceuticals Corp. (Nasdaq: PHIO) has announced the rescheduling of its fireside chat with H.C. Wainwright, originally set for June 22, 2021. The new date is July 12, 2021, at 11 a.m. Eastern Time. Phio focuses on developing immuno-oncology therapeutics using its proprietary self-delivering RNAi (INTASYL™) platform, aimed at enhancing immune response against tumors. Investors can expect more details on the rescheduled event soon.
Phio Pharmaceuticals Corp. (Nasdaq: PHIO) announces CEO Dr. Gerrit Dispersyn's participation in two key virtual events: the AGP Summer Healthcare Symposium on June 17, 2021 and a fireside chat hosted by H.C. Wainwright on June 22, 2021. These platforms will highlight the company's innovative self-delivering RNAi (INTASYL™) therapeutic platform, which aims to enhance immuno-oncology treatments. Interested parties can register for the fireside chat and access future webcasts via the company’s website.
Phio Pharmaceuticals Corp. (Nasdaq: PHIO) announced positive in vivo study results at the June 2021 ASCO Annual Meeting, showcasing its INTASYL™ RNAi therapy platform's efficacy in targeting BRD4 and PD-1 proteins. The dual-targeting approach led to complete tumor responses in 83% of tested mice, outperforming conventional treatments like JQ-1 and anti-PD-1 monoclonal antibodies. The study also indicated a superior safety profile for the INTASYL treatment. These findings emphasize INTASYL's potential in improving immuno-oncology therapies.
Phio Pharmaceuticals Corp. (Nasdaq: PHIO) reported financial results for Q1 2021, highlighting strong momentum in its pipeline. The company has significant data supporting its INTASYL compounds, showing potential to enhance CAR-T therapy efficacy. A clinical study for PH-762 in advanced melanoma is set to commence in Q4 2021, conducted at the Gustave Roussy Institute. Cash reserves reached $32.7 million, sufficient to fund operations into Q2 2023, despite a net loss of $3.4 million for the quarter. R&D expenses rose to $2.6 million, reflecting increased preclinical study costs.
Phio Pharmaceuticals Corp. (Nasdaq: PHIO) announced promising in vivo data on May 11, 2021, indicating that its compound PH-762 significantly boosts the antitumor efficacy of HER2-targeted CAR-T cells against solid tumors, particularly in a mouse model of ovarian cancer. The results show approximately 90% PD-1 silencing in HER2CART cells, enhancing their effectiveness without affecting cell viability. This breakthrough could improve T cell-based immunotherapies, addressing challenges faced by traditional CAR T-cell therapies in solid tumors.
Phio Pharmaceuticals Corp. (Nasdaq: PHIO) announced new data presentations at the upcoming 24th Annual Meeting of the ASGCT (May 11-14, 2021) and the ASCO Annual Meeting (June 4-8, 2021). At ASGCT, the poster titled "INTASYL PH-762 Self-Delivering RNAi Targeting PD-1 Enhances the Therapeutic Efficacy of HER2-Targeted CAR-T Cells" will be presented by Benjamin Cuiffo et al. Additionally, ASCO will feature a poster on INTASYL therapy targeting BRD4 and PD-1. Archived presentations will be available on the company's website.